Effects of Recombinant Human DNase Therapy on Healthcare use and Costs in Patients with Cystic Fibrosis
- 1 May 1995
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 29 (5), 459-464
- https://doi.org/10.1177/106002809502900501
Abstract
To assess the effects of recombinant human DNase (rhDNase) therapy on the cost of treating respiratory tract infections (RTIs) in patients with cystic fibrosis. We prospectively documented the use of healthcare services among 968 patients with cystic fibrosis who participated in a recent Phase III double-blind, multicenter, clinical trial in which patients were assigned randomly to receive either rhDNase 2.5 mg once daily, rhDNase 2.5 mg twice daily, or placebo. All patients were followed for 24 weeks. Data from secondary sources were used to estimate a total cost of RTI-related care (excluding the cost of study therapy) for each trial participant, based on observed levels of resource use. Number of RTI-related hospital admissions, days of RTI-related outpatient antibiotic therapy (intravenous and oral), and total costs of RTI-related care (excluding the cost of study therapy). Patients randomized to receive rhDNase once daily averaged 0.15 fewer RTI-related hospital admissions (0.41 vs 0.56 for placebo; p < 0.05) and 1.5 fewer days of RTI-related outpatient intravenous antibiotic therapy (2.9 vs 4.4; p < 0.05). Patients randomized to receive rhDNase twice daily had 0.14 fewer hospital admissions (p < 0.01), but no reduction in outpatient intravenous antibiotic therapy. Compared with placebo, the cost of treating RTIs over 24 weeks was $814-1682 less among patients receiving rhDNase. rhDNase therapy reduced the costs of treating RTIs in patients with cystic fibrosis; assuming once-daily dosing, these savings would offset about one-third of the cost of such therapy.Keywords
This publication has 10 references indexed in Scilit:
- Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic FibrosisThe New England Journal of Medicine, 1994
- Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosisThe Lancet, 1993
- Efficacy and Safety of Short-term Administration of Aerosolized Recombinant Human Deoxyribonuclease in Patients with Cystic FibrosisAmerican Review of Respiratory Disease, 1993
- The changing epidemiology of cystic fibrosisThe Journal of Pediatrics, 1993
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin DiseaseAnnals of Internal Medicine, 1992
- Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.Proceedings of the National Academy of Sciences of the United States of America, 1990
- Rapid Estimation of Hospital Charges in Patients with LeukemiaMedical Care, 1989
- Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary diseaseThe Journal of Pediatrics, 1987
- Rapid Estimation of Hospitalization Charges From a Brief Medical Record ReviewMedical Care, 1986
- Identifying Costs of Medical CareJAMA, 1985